Hemogenyx Pharmaceuticals PLC Posting of Annual Report & Notice of AGM (4119Q)

TIDMHEMO

RNS Number : 4119Q

Hemogenyx Pharmaceuticals PLC

05 June 2018

Hemogenyx Pharmaceuticals Plc

("Hemogenyx" or the "Company")

Posting of Annual Report

& Notice of Annual General Meeting

Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, confirms that the Annual Report and Accounts for the year ended 31 December 2017 ("2017 Annual Report"), the Notice of the Annual General Meeting and a Form of Proxy are now available on the Company's website:

https://www.hemogenyx.com/investors/annual-and-half-year-reports/default.aspx

The 2017 Annual Report will be posted to shareholders today.

The AGM is to be held on 27 June 2018 at 11am at the offices of Charles Russell Speechlys LLP, 5 Fleet Place, London, EC4M 7RD.

Enquiries:

 
 Hemogenyx Pharmaceuticals Limited                                           www.hemogenyx.com 
 Dr Vladislav Sandler, Chief Executive                                         Via Walbrook PR 
  Officer & Co-Founder 
 Sir Marc Feldmann, Executive Chairman 
 
 Optiva Securities Ltd                                                     Tel: [phone] 
                                                                                          1902 
 Christian Dennis 
 
 Shard Capital Partners LLP                                                Tel: [phone] 
                                                                                          9950 
 Damon Heath, Erik Woolgar 
 
 Peterhouse Corporate Finance Limited                                      Tel: [phone] 
                                                                                          0930 
 Lucy Williams, Duncan Vasey 
 
 Walbrook PR (UK Media &                                           Tel: [phone] or 
  Investor Relations)                                                 [e-mail] 
 Paul McManus                                                         Mob: [phone] 
 
 US Media enquiries 
 Lowell Goodman                            Tel: [phone] or [e-mail] 
 
 

About Hemogenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, HemoGenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York. HemoGenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. HemoGenyx's two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care. For more information, visit www.hemogenyx.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCFAMRTMBMMBIP

(END) Dow Jones Newswires

June 05, 2018 13:05 ET (17:05 GMT)